Results 101 to 110 of about 1,885,895 (335)

Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update.

Pharmacological Research
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century.
R. Roskoski
semanticscholar   +1 more source

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options

Clinical Pharmacokinetics, 2017
Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have been shown to be effective in a wide variety of solid and hematologic malignancies.
R. V. van Leeuwen, F. Jansman, N. Hunfeld, R. Peric, A. Reyners, A. L. T. Imholz, J. Brouwers, J. Aerts, T. van Gelder, R. Mathijssen   +9 more
semanticscholar   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

pharmacological application of tyrosine kinase inhibitors in certain malinancies

, 2019
The use of targeted therapy to inhibit tyrosine kinases, as a form of cancer chemotherapy is one of the major medical advances in the past decade. Tyrosine kinases activate many signal transduction cascades by adding a phosphate group to proteins and ...
Peslin, Pavel
core  

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes

Stem Cell Reports, 2019
Summary: Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF).
Sanam Shafaattalab, Eric Lin, Effimia Christidi, Haojun Huang, Yulia Nartiss, Analucia Garcia, Jeehon Lee, Stephanie Protze, Gordon Keller, Liam Brunham, Glen F. Tibbits, Zachary Laksman   +11 more
doaj   +1 more source

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

International Journal of Molecular Sciences, 2018
Tyrosine kinase inhibitors are a rapidly expanding class of molecular targeted therapies for the treatment of various types of cancer and other diseases.
Klarissa D Jackson, Rebecca Durandis, M. Vergne   +2 more
semanticscholar   +1 more source

High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase [PDF]

, 2011
<p><b>Background:</b> <i>Leishmania</i> species are parasitic protozoa that have a tightly controlled cell cycle, regulated by cyclin-dependent kinases (CDKs).
Mottram Jeremy C., Thomson, Graeme, Mottram, JC, Grant Karen M., Turner, N.J., Malcolm D. Walkinshaw, Malone, Kirk, Turner, Nicholas J., Nicholas J Turner, Jeremy C. Mottram, Karen M. Grant, Walker, Roderick G., Kita, K, Graeme Thomson, Malone Kirk, Karen M Grant, Grant, Karen, Nicholas J. Turner, Walker, RG, Nowicki, Matthew W., Thomson Graeme, Walkinshaw, M.D., Walkinshaw Malcolm D., David G. Blake, David G Blake, Walker Roderick G., Brown, Elaine, Brown Elaine, Blake David G., Brown, E, Malone, K, Turner Nicholas J., Walkinshaw, MD, Blake, DG, Matthew W. Nowicki, Walker, R.G., Malone, K., Blake, David G., Elaine Brown, Mottram, J.C., Kirk Malone, Walkinshaw, Malcolm D., Matthew W Nowicki, Nowicki, MW, Brown, E., Nowicki Matthew W., Turner, Nicholas J.; id_orcid, Grant, Karen M., Grant, K.M., Mottram, Jeremy C., Roderick G Walker, Thomson, G, Jeremy C Mottram, Roderick G. Walker, Nowicki, M.W., Grant, KM, Blake, D.G., Malcolm D Walkinshaw, Turner, NJ, Thomson, G.   +59 more
core   +2 more sources

SÍNTESES E PROPRIEDADES DE FÁRMACOS INIBIDORES DA TIROSINA QUINASE BCR-ABL, UTILIZADOS NO TRATAMENTO DA LEUCEMIA MIELOIDE CRÔNICA

Química Nova
The chronic myeloid leukemia (CML) is characterized by presence of the Philadelphia chromosome (Ph), originated from the translocation between chromosomes 9 and 22.
Liviane D. de Azevedo, Mônica M. Bastos, Andressa Paula de Oliveira, Núbia Boechat   +3 more
doaj   +1 more source